The U.S. Food and Drug Administration (FDA) on Friday granted accelerated approval for the experimental dementia drug lecanemab.
Lecanemab, which will be marketed as Leqembi, is the second of a new class of Alzheimer’s disease drugs that target the illness’s core pathophysiology, according to the FDA, which said the drug is a significant step forward in the ongoing battle to treat Alzheimer’s disease properly.
The first class of drug, aducanumab, was approved by the FDA in June 2021. That drug, marketed as Aduhelm, addresses the underlying cause of the disease rather than the symptoms. Both drugs are made by the Japanese company Eisai Biologics….